Brokerages Set Twist Bioscience Corporation (NASDAQ:TWST) Target Price at $50.40

Twist Bioscience Corporation (NASDAQ:TWST) has been assigned an average recommendation of “Moderate Buy” from the ten research firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $50.40.

TWST has been the subject of a number of recent research reports. JPMorgan Chase & Co. cut their price objective on Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating for the company in a research report on Tuesday, May 6th. The Goldman Sachs Group reduced their target price on Twist Bioscience from $55.00 to $48.00 and set a “buy” rating for the company in a report on Tuesday, May 6th. Barclays reduced their target price on Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating for the company in a report on Thursday, April 10th. Guggenheim restated a “buy” rating and issued a $50.00 target price on shares of Twist Bioscience in a report on Tuesday, May 6th. Finally, Robert W. Baird reduced their target price on Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating for the company in a report on Tuesday, May 6th.

Twist Bioscience Price Performance

Shares of NASDAQ:TWST opened at $38.11 on Wednesday. Twist Bioscience has a one year low of $27.12 and a one year high of $60.90. The stock has a fifty day moving average of $33.49 and a 200-day moving average of $40.22. The company has a market capitalization of $2.28 billion, a PE ratio of -11.73 and a beta of 2.41. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.24 and a current ratio of 4.51.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 54.98% and a negative return on equity of 33.48%. The company had revenue of $92.79 million for the quarter, compared to analyst estimates of $92.00 million. As a group, equities analysts anticipate that Twist Bioscience will post -2.12 EPS for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In related news, CFO Adam Laponis sold 936 shares of the stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $29.75, for a total transaction of $27,846.00. Following the completion of the sale, the chief financial officer directly owned 106,018 shares in the company, valued at approximately $3,154,035.50. This trade represents a 0.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Paula Green sold 1,101 shares of the stock in a transaction on Monday, May 5th. The stock was sold at an average price of $37.65, for a total value of $41,452.65. Following the sale, the senior vice president owned 129,380 shares of the company’s stock, valued at approximately $4,871,157. This represents a 0.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 21,911 shares of company stock valued at $761,826 in the last quarter. Corporate insiders own 3.01% of the company’s stock.

Hedge Funds Weigh In On Twist Bioscience

Several hedge funds have recently bought and sold shares of the business. Arizona State Retirement System increased its position in Twist Bioscience by 1.3% during the fourth quarter. Arizona State Retirement System now owns 16,985 shares of the company’s stock worth $789,000 after buying an additional 219 shares during the last quarter. Hillsdale Investment Management Inc. increased its position in Twist Bioscience by 0.4% during the fourth quarter. Hillsdale Investment Management Inc. now owns 78,000 shares of the company’s stock worth $3,625,000 after buying an additional 300 shares during the last quarter. GAMMA Investing LLC increased its position in Twist Bioscience by 68.1% during the first quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock worth $29,000 after buying an additional 303 shares during the last quarter. Deerfield Management Company L.P. Series C increased its position in Twist Bioscience by 1.7% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 23,827 shares of the company’s stock worth $1,107,000 after buying an additional 403 shares during the last quarter. Finally, Summit Investment Advisors Inc. grew its position in shares of Twist Bioscience by 7.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,098 shares of the company’s stock valued at $283,000 after purchasing an additional 443 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.